Clinical Trials · NCT00415246
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Ipsen
- Enrollment
- 100
- Start date
- Nov 2006
- Locations
- 31 sites, 8 countries
- Primary endpoint
- Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.